bioTheranostics, part of the worldwide bioMérieux group, discovers, develops, and commercializes molecular-based diagnostic, prognostic, and predictive tests that support physicians in the treatment of patients with cancer. The company operates a CLIA-certified, CAP-accredited diagnostic service laboratory in San Diego, CA.
Cancer is the number two cause of death in the United States, killing 565,650 people annually. Although there has been significant progress in the treatment of cancer over the past 20 years, the overall five-year survival rate is still only 66%.1
The majority of promising new cancer drugs target selected cancer-activated pathways. Knowledge of the primary tumor site is fundamental to guiding and optimizing treatment selection for patients.2
bioTheranostics is partnered with a network of top-tier clinical and academic leaders who share a vision for the future of cancer diagnostics. These collaborators include researchers from Harvard Medical School/MGH, MD Anderson Cancer Center, Mayo Clinic, Baylor College of Medicine, Sharp Hospital in San Diego, Jules Bordet Institute (Belgium), the Erasmus Medical Center (Rotterdam), and the Sarah Cannon Research Institute.
bioTheranostics has developed molecular-based tests that are objective and quantifiable. CancerTYPE ID® and Breast Cancer IndexSM are real time RT-PCR based assays compatible with readily available, formalin-fixed paraffin embedded (FFPE) needle core biopsies, excisional biopsies, and surgical samples.
1Source: Cancer Facts & Figures 2008, American Cancer Society
2Source: National Cancer Institute Cancer Information Summaries: Adult Treatment.